Keyphrases
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
100%
Age-related
16%
Autologous Mesenchymal Stem Cells
16%
Autologous Stem Cells
16%
Bioactive Molecules
16%
Central Nervous System Inflammation
16%
Clinical Trial Phases
16%
Demyelination
33%
Disease Onset
16%
Disease Prevention
16%
Donor Age
16%
Donor Cells
33%
Effective Therapy
16%
Experimental Autoimmune Encephalomyelitis
33%
Experimental Autoimmune Encephalomyelitis Mice
100%
Hepatocyte Growth Factor
16%
Human Adipose-derived Stem Cells (hADSCs)
100%
Immunomodulation
16%
Mature Oligodendrocyte
16%
Mesenchymal Stem Cell Therapy
16%
Mouse Model
100%
Multiple Sclerosis
33%
Neurodegeneration
16%
Neuroprotection
16%
Older Donors
66%
Older Patients
16%
Physiological Aging
16%
Progressive multiple Sclerosis
16%
Proliferation in Vitro
16%
Remission
16%
Splenocyte Proliferation
16%
Stem Cell-derived
33%
Stem Cells
16%
Therapeutic Effectiveness
16%
Therapeutic Efficacy
16%
Young Donors
50%
Medicine and Dentistry
Adipose Derived Stem Cell
100%
Adipose-Derived Mesenchymal Stem Cell
100%
Central Nervous System
16%
Clinical Trial
16%
Combination Therapy
16%
Demyelination
16%
Disease
16%
Experimental Autoimmune Encephalomyelitis
100%
Immunomodulation
16%
In Vitro
33%
Mesenchymal Stem Cell Transplantation
16%
Multiple Sclerosis
50%
Myelin
16%
Neurodegeneration
16%
Neuroinflammation
16%
Neuroprotection
16%
Oligodendrocyte
16%
Prophylaxis
16%
Remyelination
16%
Scatter Factor
16%
Stem Cell
33%
Neuroscience
Adipose Tissue
100%
Cell Therapy
14%
Central Nervous System
14%
Experimental Autoimmune Encephalomyelitis
100%
Hepatocyte Growth Factor
14%
In Vitro
28%
Mesenchymal Stem Cell
100%
Multiple Sclerosis
28%
Myelin
14%
Neurodegeneration
14%
Neuroprotection
14%
Oligodendrocyte
14%
Primary Progressive Multiple Sclerosis
14%
Remyelinization
14%
Splenocyte
14%
Stem Cell
100%